A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lazertinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Hematology/oncology and stem cell therapy Pub Date : 2025-06-20 DOI:10.4103/hemoncstem.HEMONCSTEM-D-24-00041

Louis Fabio Jonathan Jusni, Eric Ricardo Yonatan, Nicolas Daniel Widjanarko, Rio Gusta Notario Besri

{"title":"A Systematic Review and Meta-Analysis of the Efficacy and Safety of Lazertinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).","authors":"Louis Fabio Jonathan Jusni, Eric Ricardo Yonatan, Nicolas Daniel Widjanarko, Rio Gusta Notario Besri","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00041","DOIUrl":null,"url":null,"abstract":"Background and objective: Epidermal growth factor receptor (EGFR) mutations are a common driver of oncogenesis in non-small cell lung cancer (NSCLC). Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has shown promise as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated NSCLC. However, the comparative efficacy and safety of lazertinib in this setting have not been thoroughly investigated. This study aims to evaluate the efficacy and safety of lazertinib for EGFR-mutated locally advanced NSCLC.Method: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We performed a search of PubMed, ProQuest, EBSCO, and ScienceDirect to identify eligible studies based on the PICOTS-SD criteria. The meta-analysis of overall survival (OS), progression-free survival (PFS), and adverse effects was performed using RevMan 5.4 software.Results: This review included a total of three randomized controlled trials. The pooled analysis revealed significant differences in PFS, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI]: 0.37-0.53). However, OS showed no significant differences, with an HR of 0.82 (95% CI: 0.64-1.06). Paresthesia occurred significantly more frequently in the lazertinib group (odds ratio [OR]: 11.30; 95% CI: 7.30-17.49). In contrast, the incidence of diarrhea and increases in Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) levels were significantly higher in the gefitinib group, with ORs of 0.52 (95% CI: 0.39-0.70), 0.35 (95% CI: 0.25-0.50), and 0.32 (95% CI: 0.22-0.47), respectively.Conclusion: Lazertinib demonstrated a greater therapeutic benefit for patients with EGFR-mutated advanced NSCLC compared to first-generation EGFR-TKIs. Further research is needed to validate these findings.","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/oncology and stem cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Epidermal growth factor receptor (EGFR) mutations are a common driver of oncogenesis in non-small cell lung cancer (NSCLC). Lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has shown promise as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated NSCLC. However, the comparative efficacy and safety of lazertinib in this setting have not been thoroughly investigated. This study aims to evaluate the efficacy and safety of lazertinib for EGFR-mutated locally advanced NSCLC.

Method: This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We performed a search of PubMed, ProQuest, EBSCO, and ScienceDirect to identify eligible studies based on the PICOTS-SD criteria. The meta-analysis of overall survival (OS), progression-free survival (PFS), and adverse effects was performed using RevMan 5.4 software.

Results: This review included a total of three randomized controlled trials. The pooled analysis revealed significant differences in PFS, with a hazard ratio (HR) of 0.44 (95% confidence interval [CI]: 0.37-0.53). However, OS showed no significant differences, with an HR of 0.82 (95% CI: 0.64-1.06). Paresthesia occurred significantly more frequently in the lazertinib group (odds ratio [OR]: 11.30; 95% CI: 7.30-17.49). In contrast, the incidence of diarrhea and increases in Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) levels were significantly higher in the gefitinib group, with ORs of 0.52 (95% CI: 0.39-0.70), 0.35 (95% CI: 0.25-0.50), and 0.32 (95% CI: 0.22-0.47), respectively.

Conclusion: Lazertinib demonstrated a greater therapeutic benefit for patients with EGFR-mutated advanced NSCLC compared to first-generation EGFR-TKIs. Further research is needed to validate these findings.

查看原文本刊更多论文

Lazertinib作为egfr突变的局部晚期或转移性非小细胞肺癌（NSCLC）一线治疗的疗效和安全性的系统评价和荟萃分析。

背景与目的：表皮生长因子受体（EGFR）突变是非小细胞肺癌（NSCLC）肿瘤发生的常见驱动因素。Lazertinib是第三代EGFR酪氨酸激酶抑制剂（TKI），有望作为局部晚期或转移性EGFR突变的NSCLC患者的一线治疗药物。然而，在这种情况下，拉泽替尼的相对疗效和安全性尚未得到彻底的研究。本研究旨在评估lazertinib治疗egfr突变的局部晚期NSCLC的疗效和安全性。方法：本研究遵循系统评价和荟萃分析指南的首选报告项目进行。我们检索PubMed、ProQuest、EBSCO和ScienceDirect，根据PICOTS-SD标准确定符合条件的研究。采用RevMan 5.4软件对总生存期（OS）、无进展生存期（PFS）和不良反应进行meta分析。结果：本综述共纳入3项随机对照试验。合并分析显示PFS差异显著，风险比（HR）为0.44（95%可信区间[CI]: 0.37-0.53）。然而，OS无显著差异，HR为0.82 （95% CI: 0.64-1.06）。拉泽替尼组发生感觉异常的频率明显更高(优势比[OR]: 11.30；95% ci: 7.30-17.49)。相比之下，吉非替尼组腹泻发生率和谷丙转氨酶（ALT）和谷草转氨酶（AST）水平升高显著高于对照组，or分别为0.52 （95% CI: 0.39-0.70）、0.35 （95% CI: 0.25-0.50）和0.32 （95% CI: 0.22-0.47）。结论：与第一代EGFR-TKIs相比，Lazertinib对egfr突变的晚期NSCLC患者显示出更大的治疗益处。需要进一步的研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology/oncology and stem cell therapy

自引率

0.00%

发文量